Nevertheless, given both the synergistic response to dual therapy seen in AML and the limited efficacy of mutIDH inhibitor monotherapy in glioma trials, further investigation of combination DNMT inhibitor and mutIDH inhibitor therapy in glioma is warranted. This evidence concerns the gene DNMT1 and acute myeloid leukemia.